Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Allarity Therapeutics, Inc. incurred convertible notes of $660,000 with 3i, LP at 8% per annum maturing March 14, 2025.
- Instrument
- convertible notes
- Principal
- $660,000
- Counterparty
- 3i, LP
- Rate
- 8% per annum
- Maturity
- March 14, 2025
- Event
- incurrence
Exact text from the filing
On March 14, 2024 (the “Subsequent Closing”), we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $660,000 (the “Principal Amount”) due on March 14, 2025 (the “Note,”
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Allarity Therapeutics, Inc.: Filing of Seventh Certificate of Amendment to Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock to reduce conversion price from $0.405 to $0.3501 (effective 2024-03-14).
- Change
- charter amendment
- Effective
- 2024-03-14
Exact text from the filing
On March 14, 2024, we filed the Seventh Amendment to change the “Conversion Price” from $0.405 to $0.3501.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Allarity Therapeutics, Inc. entered into Securities Purchase Agreement (Note) with 3i, LP valued at $660,000 senior convertible promissory note, 8% interest, conversion price $0.3501 (effective 2024-03-14).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- 3i, LP
- Value
- $660,000 senior convertible promissory note, 8% interest, conversion price $0.3501
- Effective
- 2024-03-14
Exact text from the filing
Item 1.01 Entry into a Material Definitive Agreement. Subsequent Closing As previously disclosed, on January 18, 2024, Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”), entered into a Securities Purchase Agreement, as amended by the First Amendment to Securities Purchase Agreement, dated as of January 25, 2024 (as so amended, the “Purchase Agreement”) with 3i, LP, a Delaware limited partnership (the “Purchaser” and together with us, the “Parties”). On March 14, 2024 (the “Subsequent Closing”), we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $660,000 (the “Principal Amount”) due on March 14, 2025 (the “Note,” and together with the Notes issued on January 18, 2024 and February 13, 2024, and the Purchase Agreement, the “Transaction Documents”) for an aggregate purchase price of $600,000, representing an approximately 10% original issue discount (the “Transaction”).
View on SEC.gov